Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration, has announced that the company's leading drug candidate, POT-4, has shown early positive safety results in its Phase I study.
Subscribe to our email newsletter
POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor.
Based on this mechanism of action, POT-4 holds the potential to be effective against both dry and wet age-related macular degeneration (AMD), the company said.
Cedric Francois, president and CEO of Potentia. “As a result of the favorable early data, it was decided to expand the trial to permit further dose escalation, with the goal of prolonging the pharmacological benefit from POT-4.
“Potentia looks forward to the presentation of the Phase I data at a future medical conference and, with additional information gained from the extension of the study, to the initiation of Phase II trials in the future.”